Ochre Bio Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ochre Bio Limited - overview
Established
2019
Location
Oxford, -, UK
Primary Industry
Biotechnology
About
Founded in 2019 and based in Oxford, UK, Ochre Bio Limited operates as a developer of AI-integrated drug development procedure for genomic medicines called deep phenotyping that helps in shutting down over-active genes for livers before transplant. The company was founded by the CEO Jack O'meara and Quin Wills. In June 2021, the company received its first seed funding from a group of investors that includes Khosla Ventures, Backed VC, and Appolo Health Ventures. The company's product is focusing on developing a genomic medicine that uses an AI-integrated drug development procedure called deep phenotyping.
The medicine focuses on shutting down the over-active genes that cause chronic liver diseases. The formula specifically targets the liver that will undergo transplants or under medication. The company's revenue is generated by the sales of its RNA medicines to its target market mostly patients that will undergo transplants and under medications. The company plans to expand its platform to identify and validate new liver targets.
Current Investors
Khosla Ventures, Hoxton Ventures, Backed VC
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.ochre-bio.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Ochre Bio Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.